Bailard’s Ocular Therapeutix OCUL Stock Holding History

Bailard’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-146,752	Closed	-$907K	–	444
2017 Q3	$907K	Hold	146,752	–	–	0.07%	173
2017 Q2	$1.36M	Hold	146,752	–	–	0.11%	156
2017 Q1	$1.36M	Sell	146,752 -100,000	-41%	-$833K	0.11%	156
2016 Q4	$2.06M	Sell	246,752 -68,000	-22%	-$527K	0.19%	122
2016 Q3	$2.16M	Buy	314,752 +95,000	+43%	+$579K	0.2%	114
2016 Q2	$1.09M	Hold	219,752	–	–	0.13%	154
2016 Q1	$2.12M	Buy	+219,752	New	+$1.66M	0.3%	62
2015 Q4	–	Sell	-92,000	Closed	-$1.29M	–	295
2015 Q3	$1.29M	Buy	92,000 +37,000	+67%	+$743K	0.2%	78
2015 Q2	$1.16M	Hold	55,000	–	–	0.18%	94
2015 Q1	$2.31M	Buy	+55,000	New	+$1.81M	0.32%	53

Other funds holding OCUL

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bailard's OCUL Position: Q4 2017 in Review

Bailard sold out of Ocular Therapeutix (OCUL) in Q4 2017, closing a stake of 146,752 shares — an estimated $907K sold.

Bailard first reported a position in OCUL in Q1 2015 and held it in 10 quarters. The position peaked at $2.31M in Q1 2015. 69 funds tracked by Wall St. Rank hold OCUL as of Q4 2017.

Bailard reported no remaining Ocular Therapeutix position as of Q4 2017 after selling out during the quarter.
Bailard sold 146,752 Ocular Therapeutix shares in Q4 2017, an estimated $907K.
Bailard first reported a position in Ocular Therapeutix in Q1 2015 and held it in 10 quarters.
Bailard's Ocular Therapeutix position peaked at $2.31M in Q1 2015.
69 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2017.

Based on Bailard's 13F filing for Q4 2017, filed 8 Feb 2018.